DAPK1 and neoplasm: Next, we found that the DAPK1/p53/Ets-1/IKKβ/MDM2/GADD45α cascade was also active in HepG2 cells treated with other tumor therapeutic agents, such as VP-16 and 5-Fu (Fig. 8g and Fig. S3).